Study to Assess the Immune Response, the Safety and the Reactogenicity of Respiratory Syncytial Virus (RSV) Prefusion Protein 3 Older Adult (OA) (RSVPreF3 OA) Investigational Vaccine When co Administered With PCV20 in Older Adults

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2023
The purpose of this study is to assess the ability of RSVPreF3 OA investigational vaccine to generate an immune response when given in combination with PCV20 and its safety in older adults, aged ≥60 years of age.
Epistemonikos ID: 2d0d1186dec82794c327f5232c57c3506ea1e09f
First added on: Oct 02, 2023